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Description
The STarT (Subgroups for Targeted Treatment) Back 
Screening Tool (SBST) is a brief screening questionnaire 
designed for directing initial treatment for low back pain 
(LBP) in primary care. There are 9 items that assess physical 
(leg pain, co-morbid pain, and disability) and psychosocial 
(bothersomeness, catastrophising, fear, anxiety, and 
depression) factors previously found to be strong indicators 
of poor prognosis. As the tool was developed with the 
primary purpose of guiding initial treatment, only 
prognostic factors deemed to be modiﬁable were included.
Patients are asked to either agree or disagree with each 
of the 9 statements, except for bothersomeness, which 
uses a Likert scale (ranging from not at all to extremely 
bothersome). The total score (Q 1–9) and psychosocial 
subscale score (Q 5–9) are both calculated. A total score 
of ) 4/9 allocates the patient to the ‘low risk’ group. Scores 
of * 4 and * 4 on the psychosocial subscale allocates a 
patient to the ‘high risk’ group. A score * 4 but ) 4 on the 
psychosocial subscale allocates a patient to the ‘medium 
risk’ group. The SBST takes approximately 2 minutes to 
complete and is available at: http://www.keele.ac.uk/sbst/
The discriminant validity of the SBST has been shown 
to range from ‘acceptable’ (AUC 0.73 for leg pain) to 
‘outstanding’ (AUC 0.92 for disability), and has substantial 
test-retest reliability (Quadratic Weighted Kappa 0.73) (Hill 
et al 2008). Discriminant validity across the physical and 
psychosocial constructs of the SBST was similarly high for 
external samples in the UK, US, and Denmark (Hill et al 
2008, Fritz et al 2011, Mors et al 2011). Subgroup cutoff 
scores were set by using an ROC analysis. Hill et al (2008) 
found good predictive ability for these cutoff scores (High-
risk cutoff speciﬁcity 94.6%, sensitivity 39.6%; Low-risk 
cutoff speciﬁcity 65.4%, sensitivity 80.1%).
There is good agreement between the SBST scores and 
the reference standard OMPSQ (Spearman’s r = 0.8), 
showing good concurrent validity (Hill et al 2010a). Direct 
comparison on predictive validity has not been reported, 
although similar AUCs for the two tools have been found 
(OMPSQ 0.68–0.83 cf SBST 0.8)(Hockings et al 2008, Hill 
et al 2010a). The SBST has demonstrated relatively poor 
agreement with expert clinical opinion (Cohen’s Kappa = 
0.22) (Hill et al 2010b). In patients receiving physiotherapy 
care the SBST has shown superior responsiveness compared 
with several single construct measures (Wideman et al 
2012, Beneciuk et al 2012). A 2.5 score change on the SBST 
could predict ‘improved’ disability at 6 month follow-up 
(AUC 0.802) (Wideman et al 2012).
Commentary
Nearly 40% of people presenting to primary care with LBP 
are at a high risk of developing chronic disability (Henschke 
et al 2008). It is generally accepted that the one-size-ﬁts-all 
approach to treating LBP produces disappointing results 
in physiotherapy practice. The SBST has been rigorously 
developed and used in one of the ﬁrst trials to demonstrate 
improved outcomes with a stratiﬁed care approach in 
LBP (Hill et al 2011). It has since been translated into 17 
languages and is currently being validated in six countries.
The SBST can provide the physiotherapist with a consistent 
and valid indication of overall prognostic complexity. The 
tool has comparable clinimetrics properties to the current 
reference standard screening tool (OMPSQ), and is quicker 
to complete. By providing valid subgroups in LBP, the 
tool has potential to reduce disagreement in primary care 
referrals to physiotherapy.
However, the SBST was not originally developed to be a 
robust clinical prediction rule for physiotherapists, and 
some considerations should be made before using the tool in 
this context. First, the success of the tool may depend on the 
clinical setting. Despite ﬁnding good construct validity in a 
Danish study between primary and secondary care (Mors 
et al 2013), the SBST has shown inconsistent predictive 
validity in physiotherapy (Fritz et al 2011, Beneciuk et 
al 2012) and chiropractic (Field and Newell 2012) care 
settings. Second, the high false negative rate (34–40%) 
(Hill et al 2011) means that many of the ‘low risk’ group 
will still be at risk of having a poor outcome. The SBST 
risk categories should therefore supplement and not replace 
clinical judgment. Finally, full length questionnaires may 
still be more useful for selecting and monitoring treatment 
in the high risk group (Beneciuk et al 2012).
Further research could look at including ‘resilience’ factors 
which may have a unique predictive ability for chronic pain 
(Sturgeon and Zautra 2010). Prospective validation studies 
in different cultural and clinical settings will also make the 
tool more appealing to physiotherapists.
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